论文部分内容阅读
复发性阿弗它溃疡(RAU)是常见的口腔粘膜疾病,人群中发病率为20—30％,具有周期性复发规律,发作期常给病人带来痛苦与不安。目前还没有较理想的治疗方法,有待进一步深入。表皮生长因子(EGF)在溃疡愈合方面的作用在国际上日益受到重视,本试验应用广州华生基因工程有限公司生产的含EGF的Watson细胞活素治疗RAU,观察其临床疗效和不良反应,以期为该药物临床应用提供依据。我科于1993年10—12月对细胞活素进行随机对照观察,现报告如下。
Recurrent aphthous ulcer (RAU) is a common oral mucosal disease, the incidence rate of 20-30% of the population, with a recurring regularity, the attack often gives patients pain and anxiety. At present, there is no more ideal treatment to be further developed. The role of epidermal growth factor (EGF) in the healing of ulcer is gaining more and more attention in the world. In this study, Watson cytokine containing EGF produced by Guangzhou Watson Gene Engineering Co., Ltd. was used to treat RAU. The clinical efficacy and adverse reactions were observed. Provide the basis for the clinical application of the drug. Our department in October-December 1993, a randomized controlled observation of cytokines, are reported as follows.